PURPOSE: The prognostic significance of serum interleukin (IL)-8 was evaluated in patients with metastatic breast cancer. The predictive value of serum IL-8 for the presence of occult metastatic tumor cells in bone marrow aspirates was evaluated in patients with operable and metastatic breast cancer. EXPERIMENTAL DESIGN: Serum IL-8 was measured in healthy controls, patients with operable breast cancer, and patients with untreated, progressive metastatic breast cancer. In 69 patients with either operable or advanced breast cancer, occult cytokeratin-positive cells were counted in bone marrow aspirates. RESULTS: Serum IL-8 levels are increased in 67% (52 of 77) of patients with advanced breast cancer. Overall, these levels are significantly higher in patients with breast cancer compared with healthy volunteers (P < 0.001). The IL-8 levels increase significantly in patients with more advanced disease. An elevated serum IL-8 is related to an accelerated clinical course, a higher tumor load, and the presence of liver or lymph node involvement. A multivariate analysis indicates that serum IL-8 is an independent significant factor for postrelapse survival. There was a significant difference between serum IL-8 levels in patients with or without occult cytokeratin-positive bone marrow cells (P < 0.04). Serum IL-8 levels also showed an association with the number of these cells (P < 0.01). CONCLUSIONS: Serum IL-8 is increased in patients with breast cancer and has an independent prognostic significance for postrelapse survival. The observations on the relationship between occult cytokeratin-positive bone marrow cells corroborate the concept of IL-8 acting as a contributor to the process of tumor cell dissemination. Similarly, the relationship between serum IL-8 and nodal stage at presentation deserves further study. These results further expand the concept that inflammation and inflammatory cytokines are critical components of tumor progression.
PURPOSE: The prognostic significance of serum interleukin (IL)-8 was evaluated in patients with metastatic breast cancer. The predictive value of serum IL-8 for the presence of occult metastatic tumor cells in bone marrow aspirates was evaluated in patients with operable and metastatic breast cancer. EXPERIMENTAL DESIGN: Serum IL-8 was measured in healthy controls, patients with operable breast cancer, and patients with untreated, progressive metastatic breast cancer. In 69 patients with either operable or advanced breast cancer, occult cytokeratin-positive cells were counted in bone marrow aspirates. RESULTS: Serum IL-8 levels are increased in 67% (52 of 77) of patients with advanced breast cancer. Overall, these levels are significantly higher in patients with breast cancer compared with healthy volunteers (P < 0.001). The IL-8 levels increase significantly in patients with more advanced disease. An elevated serum IL-8 is related to an accelerated clinical course, a higher tumor load, and the presence of liver or lymph node involvement. A multivariate analysis indicates that serum IL-8 is an independent significant factor for postrelapse survival. There was a significant difference between serum IL-8 levels in patients with or without occult cytokeratin-positive bone marrow cells (P < 0.04). Serum IL-8 levels also showed an association with the number of these cells (P < 0.01). CONCLUSIONS: Serum IL-8 is increased in patients with breast cancer and has an independent prognostic significance for postrelapse survival. The observations on the relationship between occult cytokeratin-positive bone marrow cells corroborate the concept of IL-8 acting as a contributor to the process of tumor cell dissemination. Similarly, the relationship between serum IL-8 and nodal stage at presentation deserves further study. These results further expand the concept that inflammation and inflammatory cytokines are critical components of tumor progression.
Authors: Zachary C Hartman; Xiao-Yi Yang; Oliver Glass; Gangjun Lei; Takuya Osada; Sandeep S Dave; Michael A Morse; Timothy M Clay; Herbert K Lyerly Journal: Cancer Res Date: 2011-04-25 Impact factor: 12.701
Authors: Yan Ning; Philipp C Manegold; Young Kwon Hong; Wu Zhang; Alexandra Pohl; Georg Lurje; Thomas Winder; Dongyun Yang; Melissa J LaBonte; Peter M Wilson; Robert D Ladner; Heinz-Josef Lenz Journal: Int J Cancer Date: 2011-05-01 Impact factor: 7.396
Authors: Evan N Cohen; Tamer M Fouad; Bang-Ning Lee; Banu K Arun; Diane Liu; Sanda Tin; Angelica M Gutierrez Barrera; Toshihide Miura; Iwao Kiyokawa; Jun Yamashita; Ricardo H Alvarez; Vicente Valero; Wendy A Woodward; Yu Shen; Naoto T Ueno; Massimo Cristofanilli; James M Reuben Journal: Breast Cancer Res Treat Date: 2019-05-03 Impact factor: 4.872
Authors: Bríd M Ryan; Ana I Robles; Andrew C McClary; Majda Haznadar; Elise D Bowman; Sharon R Pine; Derek Brown; Mohammed Khan; Kouya Shiraishi; Takashi Kohno; Hirokazu Okayama; Ramakrishna Modali; Jun Yokota; Curtis C Harris Journal: Cancer Res Date: 2014-12-05 Impact factor: 12.701